AlphaYouAB
Schedule 13D filing
AH Bio Fund II, L.P. cut its Nautilus Biotechnology, Inc. (NAUT) stake below 5%
AH Bio Fund II, L.P. reported owning 4.9% of Nautilus Biotechnology, Inc. (NAUT) (6,263,235 shares) in a Schedule 13D filed Sep 11, 2026.
A 13D means the holder may push for changes at the company.
- Disclosed
- Sep 11, 2026
- Source
- Schedule 13D
More NAUT insider and Congress trades
From a public Schedule 13D, linked above. Not investment advice, and not a recommendation to buy or sell.